Lipum’s toxicology- and safety program of SOL-116 successfully completed

Press release: Umeå, 17 June 2022. Lipum (publ) reports that the GLP toxicology- and safety program on the candidate drug (SOL-116) has been completed. The drug antibody was well tolerated also in high doses and the results supports submission of a Clinical Trial Application (CTA).

The release as fetched from its publisher. lipum.se ↗